Clare L. Scott

Clare L. Scott

Grattan Street
Parkville, VIC 3010, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 136 publications

Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.

Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.

Journal: JCO clinical cancer informatics
Published: July 10, 2026

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Journal: JAMA oncology
Published: June 25, 2026

RAD54L coordinates the nucleolar DNA damage response to maintain rDNA stability.

RAD54L coordinates the nucleolar DNA damage response to maintain rDNA stability.

Journal: The EMBO journal
Published: April 30, 2026

Ovarian cancer.

Ovarian cancer.

Journal: Nature reviews. Disease primers
Published: February 03, 2026

Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology Registry.

Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology Registry.

Journal: JCO oncology practice
Published: January 14, 2026

HCMV as an Oncomodulatory Virus in Ovarian Cancer: Implications of Viral Strain Heterogeneity, Immunomodulation, and Inflammation on the Tumour Microenvironment and Ovarian Cancer Progression.

HCMV as an Oncomodulatory Virus in Ovarian Cancer: Implications of Viral Strain Heterogeneity, Immunomodulation, and Inflammation on the Tumour Microenvironment and Ovarian Cancer Progression.

Journal: Biomolecules
Published: October 17, 2025

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma.

Journal: Journal of experimental & clinical cancer research : CR
Published: September 10, 2025

Barriers and Breakthroughs in Precision Oncology: A National Registry Study of BRCA Testing and PARP Inhibitor Uptake in Women from the National Gynae-Oncology Registry (NGOR).

Barriers and Breakthroughs in Precision Oncology: A National Registry Study of BRCA Testing and PARP Inhibitor Uptake in Women from the National Gynae-Oncology Registry (NGOR).

Journal: Cancers
Published: June 25, 2025

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Journal: British journal of cancer
Published: April 16, 2025

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 04, 2025

Interleukin-6 Is a Crucial Factor in Shaping the Inflammatory Tumor Microenvironment in Ovarian Cancer and Determining Its Hot or Cold Nature with Diagnostic and Prognostic Utilities.

Interleukin-6 Is a Crucial Factor in Shaping the Inflammatory Tumor Microenvironment in Ovarian Cancer and Determining Its Hot or Cold Nature with Diagnostic and Prognostic Utilities.

Journal: Cancers
Published: March 17, 2025

Genomics of ovarian cancers and the potential of precision medicine.

Genomics of ovarian cancers and the potential of precision medicine.

Journal: Therapeutic advances in medical oncology
Published: February 19, 2025
Showing 1-12 of 136

Last Updated: 09/26/2026